Additional combination treatment approaches, including radiation therapy, chemotherapeutic agents [35], the CDK4 inhibitors palbociclib [36], the PARP inhibitors rucaparib [37] and the MEK inhibitor trametinib [30], may be needed to maximize the eradication of tumor cells and mitigate the tumor recurrence. This evidence concerns the gene CDK4 and neoplasm.